The Traders Podcast with Rob Booker

For Episode 305 of The Traders Podcast, your host Rob Booker received a question in the TFL365 chatroom from his friend “Mavrick,” who asked about entering trades that immediately go the other way, subjecting him to a nerve-racking period before eventually becoming profitable. So, Rob asks Jason the producer (a non-trader) to address Mavrick’s question. But rest assured, Rob takes a stab at answering the question, as well. And then we conclude this episode with the epic announcement of our brand new podcast:

Today, Rob and Jason have launched a new, daily, inspirational show called the RISE AND SHINE PODCAST

[ Listen to The Podcast ]
 

Uranerz Announces Third Quarter 2014 Financial Results

CASPER, WY--(November 10, 2014) - Uranerz Energy Corporation ("Uranerz" or the "Company") (NYSE MKT: URZ) (URZ.TO) (U9E.F) is pleased to announce its financial results for the third quarter ending September 30, 2014. A full version of the financial statements is filed with the United States Securities and Exchange Commission ("SEC") and with the Canadian securities administrators (on SEDAR).

2014 Third Quarter Highlights

• First reporting of uranium sales revenue in the Company's history
• Uranium revenue of $3.9 million
• 97,000 pounds of uranium captured during the quarter

Sierra Wireless Reports Third Quarter 2014 Results

Record revenue of $143.3 million; 28% year-over-year growth

VANCOUVER, British Columbia -- Sierra Wireless, Inc. (SWIR) (SW.TO)

Third Quarter 2014 highlights

• Record revenue of $143.3 million, an increase of 27.6% compared to Q3 2013
• Non-GAAP earnings from operations of $8.4 million, an increase of 249% compared to $2.4 million in Q3 2013
• Adjusted EBITDA of $11.8 million, an increase of 101% compared to Q3 2013
• Non-GAAP EPS of $0.24 compared to $0.11 in Q3 2013

Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting

--Study Demonstrated Clinically Meaningful and Statistically Significant Improvement of Agitation in Patients with Alzheimer's Disease--

ALISO VIEJO, Calif., Oct. 13, 2014 -- Avanir Pharmaceuticals, Inc. (AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting.

In this study utilizing the two-stage, sequential parallel comparison design (SPCD), AVP-923 showed a clinically meaningful and statistically significant improvement in agitation on the primary endpoint and a majority of the secondary endpoints. Key highlights from the poster were: